Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bernstein Remains a Buy on CVS Health (CVS)

Tipranks - Tipranks - Tue Apr 14, 12:26PM CDT

Bernstein analyst Lance Wilkes maintained a Buy rating on CVS Health on April 10 and set a price target of $94.00.

Claim 30% Off TipRanks

According to TipRanks, Wilkes is an analyst with an average return of -5.2% and a 44.64% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as CVS Health, HCA Healthcare, and Centene.

In a report released on April 8, RBC Capital also maintained a Buy rating on the stock with a $93.00 price target.

See the top stocks recommended by analysts >>

Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $105.69 billion and a net profit of $2.94 billion. In comparison, last year the company earned a revenue of $97.71 billion and had a net profit of $1.64 billion

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).